Novartis | NOVN - Zinsaufwendungen Für Schuld

Aktienkurs
116.80
Täglich Wechseln
0.90 0.78%
Monatlich
-2.89%
Jährlich
30.74%
Q2 Prognose
111.13




Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 645M 69M 2026-03
Alcon AG USD 52M 2M 2026-03
Amgen USD 657M 4M 2026-03
AstraZeneca USD 484M 181M 2025-12
Autolus Therapeutics Ltd USD 22.84M 12.32M 2025-12
Bayer EUR 675M 87M 2025-12
Biogen USD 72.6M 12.6M 2025-06
Bristol-Myers Squibb USD 411M 21M 2026-03
Eli Lilly USD 114.7M 134.3M 2025-09
Fresenius EUR 81M 5M 2025-09
Fresenius Medical Care EUR 79M 6M 2026-03
Genmab DKK 10M 27M 2025-12
Gilead Sciences USD 240M 15M 2026-03
GlaxoSmithKline GBP 167M 21M 2026-03
GRIFOLS EUR 141.43M 61.28M 2025-06
Hikma Pharmaceutical USD 67M 47M 2025-12
J&J USD 43M 25M 2026-03
Lakefront Biotherapeutics EUR 1.72M 940K 2025-09
Lonza CHF 84M 14M 2025-06
Merck EUR 121M 5M 2025-12
Merck USD 479M 67M 2026-03
Novartis USD 343M 39M 2026-03
Novartis USD 281M 8M 2025-09
Novo Nordisk DKK 1.53B 3.43B 2025-09
Orion EUR 1.4M 800K 2026-03
Pfizer USD 671M 40M 2026-03
Philips EUR 83M 26M 2026-03
Recordati EUR 22.13M 1.43M 2025-12
Regeneron Pharmaceuticals USD 12.9M 700K 2026-03
Roche Holding CHF 304M 7.5M 2025-06
Sanofi EUR 178M 203M 2026-03
UCB EUR 49M 29M 2025-12